Aggarwal Vaishali, Montoya Catalina Ardila, Donnenberg Vera S, Sant Shilpa
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Department of Cardiothoracic Surgery, University of Pittsburgh, School of Medicine Pittsburgh, PA 15213, USA.
iScience. 2021 Jan 28;24(2):102113. doi: 10.1016/j.isci.2021.102113. eCollection 2021 Feb 19.
Epithelial-to-mesenchymal transition (EMT), an evolutionary conserved phenomenon, has been extensively studied to address the unresolved variable treatment response across therapeutic regimes in cancer subtypes. EMT has long been envisaged to regulate tumor invasion, migration, and therapeutic resistance during tumorigenesis. However, recently it has been highlighted that EMT involves an intermediate partial EMT (pEMT) phenotype, defined by incomplete loss of epithelial markers and incomplete gain of mesenchymal markers. It has been further emphasized that pEMT transition involves a spectrum of intermediate hybrid states on either side of pEMT spectrum. Emerging evidence underlines bi-directional crosstalk between tumor cells and surrounding microenvironment in acquisition of pEMT phenotype. Although much work is still ongoing to gain mechanistic insights into regulation of pEMT phenotype, it is evident that pEMT plays a critical role in tumor aggressiveness, invasion, migration, and metastasis along with therapeutic resistance. In this review, we focus on important role of tumor-intrinsic factors and tumor microenvironment in driving pEMT and emphasize that engineered controlled microenvironments are instrumental to provide mechanistic insights into pEMT biology. We also discuss the significance of pEMT in regulating hallmarks of tumor progression i.e. cell cycle regulation, collective migration, and therapeutic resistance. Although constantly evolving, current progress and momentum in the pEMT field holds promise to unravel new therapeutic targets to halt tumor progression at early stages as well as tackle the complex therapeutic resistance observed across many cancer types.
上皮-间质转化(EMT)是一种进化上保守的现象,人们对其进行了广泛研究,以解决癌症亚型中不同治疗方案下尚未解决的可变治疗反应问题。长期以来,人们一直设想EMT在肿瘤发生过程中调节肿瘤的侵袭、迁移和治疗抗性。然而,最近有研究强调,EMT涉及一种中间部分上皮-间质转化(pEMT)表型,其定义为上皮标志物不完全丧失和间质标志物不完全获得。进一步强调的是,pEMT转变涉及pEMT谱系两侧的一系列中间混合状态。新出现的证据强调了肿瘤细胞与周围微环境在获得pEMT表型过程中的双向串扰。尽管仍有许多工作在进行,以深入了解pEMT表型的调控机制,但很明显,pEMT在肿瘤侵袭性、侵袭、迁移和转移以及治疗抗性中起着关键作用。在这篇综述中,我们聚焦于肿瘤内在因素和肿瘤微环境在驱动pEMT中的重要作用,并强调工程化的可控微环境有助于深入了解pEMT生物学机制。我们还讨论了pEMT在调节肿瘤进展标志(即细胞周期调控、集体迁移和治疗抗性)中的意义。尽管pEMT领域不断发展,但目前的进展和势头有望揭示新的治疗靶点,以在早期阶段阻止肿瘤进展,并应对多种癌症类型中观察到的复杂治疗抗性。